Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic potential for B-cell modulation in Sjögren's syndrome.

Literature DB >> 18984420

Therapeutic potential for B-cell modulation in Sjögren's syndrome.

Abstract

B-cell hyperactivity has been recognized for a long time in Sjögren's syndrome. This B-cell activation is firstly polyclonal but can progress to monoclonal B-cell lymphoproliferation. This article addresses the therapeutic potential of B-cell modulation in Sjögren's syndrome.

Entities: Disease

Mesh：

Substances：

Year: 2008 PMID： 18984420 DOI： 10.1016/j.rdc.2008.08.014

Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN： 0889-857X Impact factor: 2.670

Keyword Cloud
Cited

8 in total

1. Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.

Authors: Barbara M Segal; Abu N M Nazmul-Hossain; Ketan Patel; Pamela Hughes; Kathy L Moser; Nelson L Rhodus
Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2011-04-16

2. Treating Sjögren's Syndrome: Insights for the Clinician.

Authors: Claudio Vitali; Gianluigi Palombi; Pierluigi Cataleta
Journal: Ther Adv Musculoskelet Dis Date: 2010-06 Impact factor: 5.346

3. Central role for marginal zone B cells in an animal model of Sjogren's syndrome.

Authors: Long Shen; Chun Gao; Lakshmanan Suresh; Zhenhua Xian; Nannan Song; Lee D Chaves; Meixing Yu; Julian L Ambrus
Journal: Clin Immunol Date: 2016-04-30 Impact factor: 3.969

Review 4. B-cell-directed therapies for autoimmune disease.

Authors: Thomas Dörner; Andreas Radbruch; Gerd R Burmester
Journal: Nat Rev Rheumatol Date: 2009-07-07 Impact factor: 20.543

5. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.

Authors: Rhona Stein; Pankaj Gupta; Xiaochuan Chen; Thomas M Cardillo; Richard R Furman; Susan Chen; Chien-Hsing Chang; David M Goldenberg
Journal: Blood Date: 2010-01-25 Impact factor: 22.113

Therapeutic potential for B-cell modulation in Sjögren's syndrome.

1. Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.

2. Treating Sjögren's Syndrome: Insights for the Clinician.

3. Central role for marginal zone B cells in an animal model of Sjogren's syndrome.

Review 4. B-cell-directed therapies for autoimmune disease.

5. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.

Review 6. What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

7. A case report of Sjögren syndrome manifesting bilateral basal ganglia lesions.

Review 8. Immunomodulatory drugs: oral and systemic adverse effects.